54.26
전일 마감가:
$53.81
열려 있는:
$54.8
하루 거래량:
1.49M
Relative Volume:
0.64
시가총액:
$10.37B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-22.51
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
-1.20%
1개월 성능:
+7.13%
6개월 성능:
+50.89%
1년 성능:
+124.49%
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
BBIO
Bridgebio Pharma Inc
|
54.26 | 10.29B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
Real time alert setup for BridgeBio Pharma Inc. performanceWeekly Trend Summary & Low Risk High Win Rate Stock Picks - newser.com
Will BridgeBio Pharma Inc. stock pay special dividendsEarnings Summary Report & Free AI Powered Buy and Sell Recommendations - newser.com
How BridgeBio Pharma Inc. (2CL) stock reacts to fiscal policiesJuly 2025 Selloffs & Fast Entry and Exit Trade Plans - newser.com
What indicators show strength in BridgeBio Pharma Inc.Fed Meeting & Real-Time Chart Pattern Alerts - newser.com
Why retail investors favor BridgeBio Pharma Inc. stock2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - newser.com
BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week - The Manila Times
BridgeBio (NASDAQ: BBIO) to present FORTIFY interim topline Oct. 27; earnings Oct. 29 - Stock Titan
Is BridgeBio Pharma Inc. stock supported by strong fundamentalsJuly 2025 Selloffs & AI Enhanced Trading Alerts - newser.com
Will BridgeBio Pharma Inc. (2CL) stock outperform value peersQuarterly Trade Review & Entry and Exit Point Strategies - newser.com
What analysts say about BridgeBio Pharma Inc stockStop Loss Placement Tips & Small Investment Capital Tips - earlytimes.in
Sentiment analysis tools applied to BridgeBio Pharma Inc.2025 Support & Resistance & Fast Gain Swing Alerts - newser.com
BridgeBio Pharma Inc. stock trend outlook and recovery path2025 Technical Patterns & Entry and Exit Point Strategies - newser.com
Leading vs lagging indicators on BridgeBio Pharma Inc. performance2025 AllTime Highs & Daily Volume Surge Signals - newser.com
Long term hold vs stop loss in BridgeBio Pharma Inc.July 2025 Retail & Free High Return Stock Watch Alerts - newser.com
Using economic indicators to assess BridgeBio Pharma Inc. potentialChart Signals & Weekly High Return Stock Opportunities - newser.com
BridgeBio Pharma stock rating reiterated as Overweight by Wells Fargo - Investing.com Canada
BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights - MSN
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Oct 08 '25 |
Sale |
54.78 |
40,000 |
2,191,350 |
855,686 |
자본화:
|
볼륨(24시간):